Patients with visible perioral wrinkles Lips rejuvenation, 675-nm laser
Conditions
Interventions
Patients were treated with the 675-nm Red Laser 3 sessions every 4 weeks.
Then they were instructed to follow up at 1, 3, and 6 months after last treatment.
Experimental Device
the 675-nm Red Laser
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male or female aged 18-60 years 2. Have Fitzpatrick Skin type III-V 3. Have perioral wrinkles using Lip Fullness Grading Scale between 0-2 assessed by dermatologist
Exclusion criteria
Exclusion criteria: 1. Patients who are pregnant, lactating, and postpartum within 1 year 2. Received Botulinum toxin injection, collagen biostimulators, platelet-rich plasma, laser, threads or energy-based devices within the last 12 months before participating in the research project 3. Patients with other skin diseases, or having infection at the area of face 4. Immunocompromised patients 5. Patients with hypertrophic scar or keloid 6. Patients with history of Cushing syndrome or Ehlers-Danlos syndrome 7. Patients with cancers or skin cancers 8. Patients with mental disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| i.Lip Fullness Grading Scale (LFGS) baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment Dermatologist,ii.Global Aesthetic Improvement Scale (GAIS) baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment Dermatologist,Volume change baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment Vectra | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment Adverse event | — |
Countries
Thailand
Contacts
Public ContactWoraphong Manuskiatti
Faculty of medicine Siriraj hospital, Mahidol university
Outcome results
None listed